Carl read the papersWhat it actually is
Matrixyl is the trade name for palmitoyl pentapeptide-4: the five amino acids Lys-Thr-Thr-Lys-Ser (KTTKS) with a palmitic acid tail. KTTKS is a small fragment of type I procollagen that, in 1993 lab work, was the minimum piece needed to switch fibroblasts up to make more collagen and fibronectin.
'Matrixyl 3000' is a different product: two other palmitoyl peptides, Pal-GHK and Pal-GQPR (palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7), supplied as a solution by Sederma, part of the Croda group. Same brand family, same collagen story, different molecules.
How it’s thought to work
- Matrikine signalling — Fragments of broken-down collagen act as a 'repair needed' signal. KTTKS mimics one and nudges fibroblasts to build matrix.
- Collagen and fibronectin — In cell culture, KTTKS was the minimum sequence needed for a potent rise in collagen and fibronectin production.
- Why the fatty tail — Both versions broke down fast in mouse skin extracts, the palmitoyl one less so. Plain KTTKS was not found in any skin layer; the palmitoyl version reached every layer, though only 0.3 mcg per square centimetre made it to the dermis.
- Surface-heavy delivery — A 2026 study on three volunteers found the Matrixyl 3000 peptides spread through the outer skin layer but sat between cells rather than inside them.
What the research says
Better than most of the skincare shelf. The key trial is from Procter and Gamble: 93 women, 12 weeks, split-face, double-blind, a moisturiser with 3 ppm Pal-KTTKS against the same moisturiser without it, with significant wrinkle improvement on image analysis. A Boots No7 serum containing palmitoyl tetrapeptide-7 (one of the two Matrixyl 3000 peptides) and a palmitoyl oligopeptide, among nine actives with retinyl palmitate included, improved wrinkles in 43% of users at 6 months against 22% on vehicle, but the difference was not significant (p = 0.10). It only pulled ahead at 12 months, against a projected placebo figure, since everyone was on the serum by then. A small Indonesian trial (21 women) favoured Pal-KTTKS over Argireline. Much of the human data comes from companies that sell it.
- KTTKS is a type I procollagen fragment that stimulated collagen and fibronectin production in cell culture.
- P&G split-face trial: 93 women, 12 weeks, 3 ppm Pal-KTTKS beat the same moisturiser without it.
- The palmitoyl version reached the dermis in mouse skin; the plain peptide did not get in at all.
- Supplier data for Matrixyl 3000: 23 women, 2 months, 3% cream twice daily, deep-wrinkle area down 39% against their own baseline.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Trial strength | 3 ppm (0.0003%) Pal-KTTKS in a moisturiser in the P&G trial. Not a typo |
| Stated use level | Sederma recommends Matrixyl 3000 at 3% of a product. That 3% is a solution whose ingredient list starts with glycerin, water and butylene glycol and puts the two peptides last |
| Frequency | Once or twice daily in the trials (the No7 trial was once daily, the Indonesian trial and the supplier study twice) |
| Timeline | 8 to 12 weeks in the trials before judging; the No7 serum never beat placebo in its 6-month controlled phase |
| Route | Topical only |
| Carl's note | Nobody has shown that more works better. The best trial used parts per million, so a 1% mix of raw powder would be over 3,000 times that strength. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Fine lines and photoaged skin | topical, daily, assessed at 8 to 12 weeks |
| Alongside Argireline | different jobs; the one small head-to-head trial favoured Matrixyl |
| What it will not do | deep folds or volume loss; it is a fine-line ingredient |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
You do not inject Matrixyl. It is a topical cosmetic ingredient, and the fatty tail exists specifically to help it into skin from the surface. The working strength is tiny: the main trial used 3 ppm. If you are mixing your own from raw powder, do the maths first, because a 1% mix would be more than 3,000 times that. Apply to clean skin once or twice daily and give it 8 to 12 weeks.
Stacks it appears in
- With Argireline — Different jobs: collagen signalling here, muscle signalling there. The only head-to-head trial we found (21 women) favoured Matrixyl.
- With GHK-Cu — Matrixyl 3000 already contains Pal-GHK, a fatty-tailed relative of GHK without the copper. Pairing them doubles up on the same sequence.
- With Snap-8 — Same logic as Argireline: different jobs in one routine.
Sources
- Katayama et al. 1993, J Biol Chem: A pentapeptide from type I procollagen promotes extracellular matrix production
- Kachooeian et al. 2022, ACS Omega: Matrixyl patch vs Matrixyl cream (identity of Matrixyl)
- Robinson et al. 2005, Int J Cosmet Sci (Procter and Gamble): Topical palmitoyl pentapeptide in photoaged facial skin
- Choi et al. 2014, Biomol Ther: Dermal stability and skin permeation of KTTKS and palmitoyl-KTTKS
- Watson et al. 2009, Br J Dermatol: Cosmetic anti-ageing product improves photoaged skin (Boots No7 serum)
- Trzaska et al. 2026, Int J Pharm: Permeation of cosmetic actives into human stratum corneum
- Aruan et al. 2023, J Clin Aesthet Dermatol: Acetylhexapeptide-3 vs palmitoyl pentapeptide-4 creams for crow's feet
- Sederma Matrixyl 3000 technical sheet (Spanish, hosted by distributor Pochteca)
- SAHPRA: Peptide Products - Public Information (May 2026)
